Pregnancy outcome after exposure to oral contraceptives during the periconceptional period

Human and Experimental Toxicology

Volumn 27, Issue 4, 2008, Pages 307-313

  Ahn, H K ^a   Choi, J S ^a   Han, J Y ^a   Kim, M H ^a   Chung, J H ^a   Ryu, H M ^a   Kim, M Y ^a   Yang, J H ^a   Koong, M K ^a   Nava Ocampo, A A ^b,c   Koren, G ^b  

^a Kwandong University College of Medicine   (South Korea)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c PharmaReasons   (Canada)

Author keywords

Birth defects; Fetal growth; Oral contraceptives; Transplacental exposure

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTREL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; RUBELLA VACCINE;

ADULT; ARTICLE; BIRTH WEIGHT; CONCEPTION; CONTROLLED STUDY; DEMOGRAPHY; FACE DYSMORPHIA; FEMALE; FETUS GROWTH; GESTATIONAL AGE; GROUPS BY AGE; HEALTH PROGRAM; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MECONIUM PERITONITIS; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; THERAPEUTIC ABORTION; CLASSIFICATION; CONGENITAL MALFORMATION; DELIVERY; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; KOREA; NEWBORN; PREMATURITY; SPONTANEOUS ABORTION; STATISTICS;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ABORTION, THERAPEUTIC; ADULT; BIRTH WEIGHT; CONTRACEPTIVES, ORAL; DELIVERY, OBSTETRIC; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; KOREA; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY OUTCOME; PREMATURE BIRTH;

EID: 52649171907     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327108092290     Document Type: Article

References (36)

1. Bracken MB. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. Obstet Gynecol 1990 ; 76: 552-527.
2. Harlap S Shiono PH Ramcharan S. Congenital abnormalities in the offspring of women who used oral and other contraceptives around the time of conception. Int J Fertil 1985 ; 30: 39-47.
3. Rothman KJ Fyler DC Goldblatt A Kreidberg MB. Exogenous hormones and other drug exposure of children with congenital heart disease. Am J Epidemiol 1979 ; 109: 433-439.
4. Janerich DT Dugan JM Standfast SJ Strite L. Congenital heart disease and prenatal exposure to exogenous sex hormones. Br Med J 1977 ; 1: 1058-1060.
5. Kricker A Elliott JW Forrest JM McCredie J. Congenital limb reduction deformities and use of oral contraceptives. Am J Obstet Gynecol 1986 ; 155: 1072-1078.
6. Czeizel A Toth J Erodi E. Aetiological studies of hypospadias in Hungary. Hum Hered 1979 ; 29: 166-171.
7. Monteleone Neto R Castilla EE Paz JE. Hypospadias: an epidemiological study in Latin America. Am J Med Genet 1981 ; 10: 5-9.
8. Kallen B. Case-control study of hypospadias, based on registry information. Teratology 1988 ; 38: 45-50.
9. Pardthaisong T Gray RH. In utero exposure to steroid contraceptives and outcome of pregnancy. Am J Epidemiol 1991 ; 134: 795-803.
10. Koren G Pastuszak A. Prevention of unnecessary pregnancy terminations by counseling women on drug, chemical, and radiation exposure during the first trimester. Teratology 1990 ; 41: 657-661.
11. Bentur Y Horlatsch N Koren G. Exposure to ionizing radiation during pregnanct: perception of teratogen risk and outcome. Teratology 1991 ; 43: 109-112.
12. Mastroiacovo P Serafini M Pagano M De Santis M Vercillo I Celestini E. The "Telefono Rosso: a service for the prevention of birth defects and for evaluation of teratogenic risk. Ann Ist Super Sanita 1993 ; 29: 115-120.
13. De Santis M Straface G Cavaliere AF Cinque B Carducci B Caruso A. Teratological risk evaluation and prevention of voluntary abortion. Minerva Ginecol 2006 ; 58: 91-99.
14. Koren G Levichek Z. The teratogenicity of drugs for nausea and vomiting of pregnancy: perceived versus true risk. Am J Obstet Gynecol 2002 ; 186 (Suppl.): S248-S252.
15. Han JY Yang JH Chung JH Choi JS Ahn HK Ryu HM. Teratogen risk counseling by internet: a prospective cohort study. J Obstet Gynaecol 2005 ; 25: 427-431.
16. Cho JS Kim KS Kim SY Kim TY Choi HM Lim YK. Congenital anomalies diagnosed by antenatal ultrasonography. J Korean Obstet Gynecol 1997 ; 40: 1228-1232.
17. Yang JH Kim YJ Chung JH Kim MY Ryu HM Ahn HK. A multi-center study for birth defect monitoring systems in Korea. J Korean Med Sci 2004 ; 19: 509-513.
18. Wilkins L Jones HW Holman GH Stempfel RS. Masculinization of the female fetus associated with administration of oral and intramuscular progestins during gestation: non-adrenal female pseudohermaphrodism. J Clin Endocrinol Metab 1958 ; 18: 559-585.
19. Grumbach MM Ducharme JR Moloshok RE. On the fetal masculinizing action of certain oral progestins. J Clin Endocrinol Metab 1959 ; 19: 1369-1380.
20. Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 1980 ; 22: 251-270.
21. Kallen B Mastroiacovo P Lancaster PA Mutchinick O Kringelbach M Martinez-Frias ML. Oral contraceptives in the etiology of isolated hypospadias. Contraception 1991 ; 44: 173-182.
22. Raman-Wilms L Tseng AL Wighardt S Einarson TR Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 1995 ; 85: 141-149.
23. Hemminki E Gissler M Toukomaa H. Exposure to female hormone drugs during pregnancy: effect on malformations and cancer. Br J Cancer 1999 ; 80: 1092-1097.
24. Hook EB. Cardiovascular birth defects and prenatal exposure to female sex hormones: a reevaluation of data reanalysis from a large prospective study. Teratology 1994 ; 49: 162-166.
25. Li DK Daling JR Mueller BA Hickok DE Fantel AG Weiss NS. Oral contraceptive use after conception in relation to the risk of congenital urinary tract anomalies. Teratology 1995 ; 51: 30-36.
26. Wilson JG Brent RL. Are female sex hormones teratogenic. Am J Obstet Gynecol 1981 ; 141: 567-580.
27. De Santis D Cavaliere AF Straface G Carducci B Caruso A. Failure of the emergency contraceptive levonorgestrel and the risk of adverse effects in pregnancy and on fetal development: an observational cohort study. Fertil Steril 2005 ; 84: 296-299.
28. Ford JH. Induction of chromosomal errors. Lancet 1973 ; 1: 54.
29. Martinez-Frias ML Bermejo E Rodriguez-Pinilla E Prieto L. Periconceptional exposure to contraceptive pills and risk for Down syndrome. J Perinatol 2001 ; 21: 288-292.
30. Kallen B. Maternal use of oral contraceptives and Down syndrome. Contraception 1989 ; 39: 503-506.
31. Ericson A Kallen B Lindsten J. Lack of correlation between contraceptive pills and Downs syndrome. Acta Obstet Gyencol Scand 1983 ; 62: 511-514.
32. Foster MA Nyberg DA Mahony BS Mack LA Marks WM Raabe RD. Meconium peritonitis: prenatal sonographic findings and their clinical significance. Radiology 1987 ; 165: 661-665.
33. http://www.fetalsono.com/Demo/DemoAns.html
34. Bianca S. Health risks of low-dose ionizing radiation in humans. Exp Biol Med (Maywood) 2005 ; 230: 99-100.
35. Shin SM Chang YP Lee ES Lee YA Son DW Kim MH. Low birth weight, very low birth weight rates and gestational age-specific birth weight distribution of Korean newborn infants. J Korean Med Sci 2005 ; 20: 182-187.
36. Brent RL;. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol 2005; 73: 906-918.